Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 29, 2023 4:24pm
186 Views
Post# 35421078

RE:RE:RE:ASCO relevance

RE:RE:RE:ASCO relevance"If Pela converts cold cancers to hot and improves survival after immunotherapy, the story is done and the share price will take care of itself. This is a multi-billion $$ indication."

Bravo Carey. We are in full agreement on this point.

Thus far the clinical results have demonstated that pelareorep to turn cold tumors "hot", and I have elaborated on how pelareorep is able to modulate INF (gamma) and downregulate HIF (alpha) to both stimulate the innate immune system and convert an otherwise immunosuppresiive tumor microenvironment (TME) for the addition of PD-(L)1 immune checkpoint inhibitors thus enabling the conversion of a cold tumor into a "hot" tumor.

Just go through all of my posts to see the immunological pathways involved in this conversion. 
<< Previous
Bullboard Posts
Next >>